Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.2%

13 terminated/withdrawn out of 249 trials

Success Rate

88.3%

+1.8% vs industry average

Late-Stage Pipeline

12%

30 trials in Phase 3/4

Results Transparency

2%

2 of 98 completed trials have results

Key Signals

23 recruiting2 with results10 terminated

Enrollment Performance

Analytics

Phase 2
100(49.0%)
N/A
62(30.4%)
Phase 3
27(13.2%)
Phase 1
12(5.9%)
Phase 4
3(1.5%)
204Total
Phase 2(100)
N/A(62)
Phase 3(27)
Phase 1(12)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (249)

Showing 20 of 249 trials
NCT03331718Phase 3Completed

PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)

Role: collaborator

NCT02551250Completed

Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis

Role: collaborator

NCT03756298Phase 2Active Not Recruiting

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Role: lead

NCT06388720Phase 2Recruiting

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Role: lead

NCT04241367Completed

Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

Role: lead

NCT06687941Phase 1Recruiting

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

Role: collaborator

NCT05827523Phase 3Recruiting

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Role: lead

NCT05673772Phase 2Active Not Recruiting

Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer

Role: collaborator

NCT05316181Phase 3Active Not Recruiting

CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)

Role: lead

NCT07405931Not ApplicableRecruiting

Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients

Role: collaborator

NCT07399561Not ApplicableNot Yet Recruiting

Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy

Role: lead

NCT06086665Completed

The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

Role: collaborator

NCT05036434Phase 2Active Not Recruiting

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Role: lead

NCT07297654Phase 2Not Yet Recruiting

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

Role: lead

NCT06828380Phase 2Recruiting

A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion

Role: lead

NCT07278102Active Not Recruiting

A Prospective Observational Study on Efficacy of TARE for Early Stage HCC

Role: collaborator

NCT07256977Not ApplicableNot Yet Recruiting

Minimally Invasive Radical Hysterectomy Using Endoscopic Stapler in Stage IB2 or IIA1 Cervical Cancer

Role: collaborator

NCT07121478Phase 2Enrolling By Invitation

Patients With High-grade Pancreatic Neuroendocrine Tumors

Role: lead

NCT07171515Enrolling By Invitation

Development & Clinical Application of K-PaC Registry Version 2.0

Role: lead

NCT07171528Phase 2Recruiting

Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer

Role: lead